- Statins can benefit men with benign prostatic hyperplasia (BPH) accompanied by metabolic syndrome (MetS) when an alpha blocker (AB) alone is ineffective.
Why this matters
- "In recent studies with the presence of MetS, therapeutic agents used for BPH and lower urinary tract symptoms (LUTS) are shown to have poor activity," say researchers. "This condition suggests that attention should be paid to the presence of MetS in the treatment of LUTS/BPH in daily practice."
- Researchers randomly assigned patients with BPH and MetS to 3 groups (N=300):
- AB (tamsulosin; Flomax) only,
- statin (atorvastatin; Lipitor) only, or
- both AB and statin.
- They then analyzed 6-month changes in each group’s International Prostate Symptom Scores (IPSS), disease-specific QoL question scores, and maximum urinary flow rates (Qmax).
- Funding: None disclosed.
- The combination therapy group showed the most significant mean change in Qmax (4.74 vs 3.16 for AB and 1.55 for statin; P<.0001>
- IPSS and QoL significantly improved in all 3 groups:
- AB: from 19.2 to 14.6 and 4.5 to 2.4, respectively.
- Statin: from 19.0 to 14.8 and 4.6 to 2.6, respectively.
- Combination: from 17.1 to 8.7 and 5.06 to 2.25, respectively.
- Researchers did not evaluate PSA changes.